In a report released today, Matthew O’Brien from Piper Sandler maintained a Buy rating on Boston Scientific (BSX – Research Report), with a ...
Alembic Global lowered the firm’s price target on Olin (OLN) to $38 from $60 and keeps an Overweight rating on the shares.Discover the Best ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results